PS
CLDX icon

Portfolio Solutions’s Celldex Therapeutics CLDX Stock Holding History

Portfolio Solutions’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-73
Closed -$3K – 56
2018
Q1 		$3K Hold
73
– – ﹤0.01% 185
2017
Q4 		$3K Hold
73
– – ﹤0.01% 172
2017
Q3 		$3K Hold
73
– – ﹤0.01% 167
2017
Q2 		$3K Hold
73
– – ﹤0.01% 155
2017
Q1 		$4K Buy
+73
New +$3.8K ﹤0.01% 172

Other funds holding CLDX

KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Portfolio Solutions's CLDX Position: Q2 2018 in Review

Portfolio Solutions sold out of Celldex Therapeutics (CLDX) in Q2 2018, closing a stake of 73 shares — an estimated $3K sold.

Portfolio Solutions first reported a position in CLDX in Q1 2017 and held it in 5 quarters. The position peaked at $4K in Q1 2017. 102 funds tracked by Wall St. Rank hold CLDX as of Q2 2018.

  • Portfolio Solutions reported no remaining Celldex Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Portfolio Solutions sold 73 Celldex Therapeutics shares in Q2 2018, an estimated $3K.
  • Portfolio Solutions first reported a position in Celldex Therapeutics in Q1 2017 and held it in 5 quarters.
  • Portfolio Solutions's Celldex Therapeutics position peaked at $4K in Q1 2017.
  • 102 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2018.

Based on Portfolio Solutions's 13F filing for Q2 2018, filed 13 Jul 2018.